if you have patients on the Repatha® prefilled single-dose syringe and need additional guidance on how to transition patients to a different device.

×
INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring ... READ MORE

For US healthcare professionals

Heart-img

IN PATIENTS AT HIGH CV RISK WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS AND WITH DIABETES*

mega-phone

NEW!

2026 ACC/AHA/ MULTISOCIETY GUIDELINE IS HERE

See what it means for your patients at increased CV risk

GraphGraph

SEE the data on CV risk reduction in patients at high CV risk without prior MI or stroke

Repatha® is now the first and only PCSK9i shown to reduce the risk of MACE in patients at high CV risk without prior MI or stroke3,4
Down Arrow IconDown Arrow Icon

VIEW CV risk reduction outcomes for patients with established CVD

Repatha® plus a statin reduced the risk of major adverse
CV events2,5

Map IconMap Icon

Explore broad coverage
and affordability

Repatha® is covered for ~96%
of patients across insurance
types6,‡

>8

million patients

have received Repatha® worldwide7,§

REVIEW SAFETY DATA
Have you seen
Amgen’s campaign?
Watch the commercial to learn what Repatha® can do for your patients
Have you seen
Amgen’s campaign?
Watch the commercial to learn what Repatha® can do for your patients

CV = cardiovascular; CVD = cardiovascular disease; IQVIA = IMS Quintiles Virtual Information Access; MI = myocardial infarction; PCSK9i = proprotein convertase subtilisin/kexin type 9 inhibitor.

‡Includes commercial, health exchange, Medicaid, and Medicare lives, as of February 2026, based on MMIT data. Inclusion on formulary does not imply superior clinical efficacy or safety. This information is subject to change without notice. For the most up-to-date and complete information regarding coverage of Repatha, please contact the relevant payer directly. Individual insurance requirements may vary.

§Cumulative postmarket exposure estimates from July 2015 through November 2025 on patients who have received at least 1 dose (estimates assume administration) of the product, which was estimated using prescription claims data (IQVIA) for the US and units distributed (Amgen Finance Electronic Data Warehouse) with average drug utilization patterns (MarketScan claims data) for all other regions. Utilization assumptions were applied to calculate the unique number of patients.

References: 1. Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes. JAMA. Published online March 28, 2026. 2. Repatha® (evolocumab) Prescribing Information, Amgen. 3. Amgen. Repatha® now indicated for adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C. News release; August 25, 2025. 4. Bohula EA. Presented at: American Heart Association; November 7-10, 2025; New Orleans, LA. 5.  Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. 6. Data on file, Amgen; [1]; 2026. 7. Data on file, Amgen; [2]; 2026.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12‑week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Indications

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
  • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and in adults with heterozygous familial hypercholesterolemia (HeFH)

Please see full Prescribing Information.

Important Safety Information

Back To Top